Welcome to our dedicated page for Cingulate SEC filings (Ticker: CING), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding a clinical-stage biotech disclosure can feel like wading through chemistry textbooks. Cingulate’s filings pack dense details on PTR™ technology, Phase 3 trial data, and patent strategies that move its valuation day to day. If you have ever asked, “How do I find Cingulate insider trading Form 4 transactions before the market reacts?” or “Where is the latest Cingulate quarterly earnings report 10-Q filing?”, you are in the right place.
Stock Titan’s AI answers the hard questions instantly. Our engine turns the 250-page Cingulate annual report 10-K simplified into a concise brief, points out R&D spend shifts, and flags liquidity runways. Real-time triggers surface Cingulate Form 4 insider transactions real-time, while plain-English summaries make Cingulate 8-K material events explained easy to digest. Trying to compare segments or trace pipeline costs? The platform links every figure back to its page so you can verify within seconds.
All filing types are covered and continuously refreshed from EDGAR: the 10-Q for quarterly pipeline progress, the proxy for Cingulate proxy statement executive compensation, and instant alerts on Cingulate executive stock transactions Form 4. Investors use these insights to monitor patent updates on CTx-1301, gauge upcoming NDA milestones, and spot buying or selling patterns that precede catalysts. Whether you need Cingulate earnings report filing analysis or are understanding Cingulate SEC documents with AI for the first time, Stock Titan puts every disclosure—explained simply—at your fingertips.
Cingulate Inc. reinstated Shane J. Schaffer as Chief Executive Officer effective December 15, 2025, ending the administrative leave that began in August 2025 due to a personal legal matter. John A. Roberts will no longer serve as Executive Chairman but remains Chairman of the Board, while Jennifer L. Callahan returns to focusing solely on her role as Chief Financial Officer.
The company states that the original charge against Dr. Schaffer was dismissed, an amended misdemeanor complaint was filed, and he pled no contest and received 12 months’ probation. On the same date, Cingulate Therapeutics LLC and Dr. Schaffer entered into an Amended and Restated Employment Agreement that restores his base salary, tightens the definition of “Cause” to include any court-determined probation violation and removes certain willfulness requirements, lowers the Board approval threshold for a cause termination from 80% to a majority, and reduces his lump-sum severance to one times base salary and annual target bonus, or one and one half times if terminated within 12 months after a change in control.
Cingulate Inc. reported a wider Q3 2025 net loss and highlighted liquidity needs as it advances its lead ADHD candidate. The company posted a net loss of
Stockholders’ equity stood at
The FDA accepted the NDA for CTx‑1301 with a PDUFA target action date of May 31, 2026. Shares outstanding were 6,757,070 as of November 11, 2025.
Cingulate Inc. (CING) furnished an 8-K announcing it issued a press release with financial results for the quarter ended September 30, 2025 and a business update. The materials were provided under Item 2.02 and are deemed furnished, not filed, which limits liability under Section 18 of the Exchange Act. The press release is included as Exhibit 99.1; the cover page Inline XBRL data file is listed as Exhibit 104.
Cingulate Inc. (CING) reported an insider equity grant. On 09/30/2025, EVP and CSO Raul Silva received a stock option covering 7,334 shares of common stock at an exercise price of $3.92, expiring 09/30/2035. The filing lists transaction code “A,” indicating an award. The option was granted pursuant to Dr. Silva’s Employment Agreement, as amended, and is held directly. Following the grant, 7,334 derivative securities were beneficially owned.
Cingulate Inc. (CING) reported a Form 4 showing its Chief Commercial Officer received a stock option grant to purchase 30,000 shares at an exercise price of $3.8 on 11/03/2025.
The option expires on 11/03/2035 and vests 25% on the one-year anniversary of the grant date, with the remaining shares vesting in substantially equal monthly installments over the following 36 months. Following the grant, 30,000 derivative securities were beneficially owned, held directly.
Cingulate Inc. (CING) disclosed an initial beneficial ownership report on Form 3 for Bryan Downey, its Chief Commercial Officer. The event date is 11/03/2025. The filing states that no securities are beneficially owned by the reporting person at the time of this report. The form was filed by one reporting person and includes an Exhibit 24 power of attorney.
Cingulate Inc. (CING) entered a financing on November 7, 2025, issuing an unsecured promissory note to Avondale Capital for a $6,570,000 principal amount that carries a 9% annual interest rate and matures in 18 months. The note was sold at a $540,000 original issue discount, generating $6,000,000 in cash proceeds for working capital and general corporate purposes.
Beginning May 7, 2026, the lender may redeem portions of the note up to $660,000 per month. The company may defer up to two redemptions for 30 days each before receiving an FDA “complete response letter,” with each deferral increasing the outstanding balance by 1%. If the note remains outstanding 90 days after its effective date, a monitoring fee applies per a formula tied to the then-outstanding balance.
Subsidiaries provided guarantees. The agreement includes customary defaults; certain defaults permit increases to the outstanding balance by 15% (Major Trigger) or 5% (Minor Trigger), each up to three times, and default interest up to 22% per year. Covenants restrict variable-rate transactions, include a most-favored-nation feature on future debt, allow prepayment, and give the lender an option (with company consent) to reinvest up to $5,000,000 on the same terms.
Cingulate Inc. announced a regulatory milestone: the FDA has accepted for review the New Drug Application for CTx-1301 (dexmethylphenidate), the company’s lead candidate for treating ADHD in children and adults. The FDA assigned a PDUFA target action date of May 31, 2026, setting the timeline for a decision after the agency’s standard review process. This step moves CTx-1301 into formal evaluation but does not indicate approval.
FAQ
What is the current stock price of Cingulate (CING)?
What is the market cap of Cingulate (CING)?
